1. AZD6738 Inhibits fibrotic response of conjunctival fibroblasts by regulating checkpoint kinase 1/P53 and PI3K/AKT pathways
   Longxiang Huang et al, 2022, Front. Pharmacol. CrossRef
2. ARPC1B promotes mesenchymal phenotype maintenance and radiotherapy resistance by blocking TRIM21-mediated degradation of IFI16 and HuR in glioma stem cells
   Zijie Gao et al, 2022, J Exp Clin Cancer Res CrossRef
3. The schedule of ATR inhibitor AZD6738 can potentiate or abolish antitumor immune responses to radiotherapy
   Frank P. Vendetti et al, 2023 CrossRef
4. AZD6738 promotes the tumor suppressive effects of trifluridine in colorectal cancer cells
   Shinnosuke Harata et al, 2023, Oncol Rep CrossRef
5. Short-Course But Not Prolonged Treatment With ATR Inhibitor AZD6738 Integrates With Radiotherapy to Generate a Tumor Antigen-Specific CD8 ⁺ T Cell Expansion in the Periphery
   Frank P. Vendetti et al, 2022, SSRN Journal CrossRef
6. Update on Emerging Therapies for Advanced Colorectal Cancer
   Olatunji B. Alese et al, 2023, American Society of Clinical Oncology Educational Book CrossRef
7. MFAE: Multilevel Feature Aggregation Enhanced Drug‐Target Affinity Prediction for Drug Repurposing Against Colorectal Cancer
   Guanxing Chen et al, 2023, Advanced Intelligent Systems CrossRef
8. Combination of S-1 and the oral ATR inhibitor ceralasertib is effective against pancreatic cancer cells
   Yoshihito Morimoto et al, 2024, Cancer Chemother Pharmacol CrossRef
9. Isovalerylspiramycin I suppresses small cell lung cancer proliferation via ATR/CHK1 mediated DNA damage response and PERK/eIF2α/ATF4/CHOP mediated ER stress
   Yongle Xu et al, 2024, Biochemical Pharmacology CrossRef
10. The Unique Pt(II)-Induced Nucleolar Stress Response and its Deviation from DNA Damage Response Pathways
    Hannah C. Pigg et al, 2024, Journal of Biological Chemistry CrossRef